Yvonne L Eaglehouse1, Evelyn O Talbott2, Yuefang Chang3, Lewis H Kuller2. 1. Division of Cancer Prevention and Population Science, Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania2Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
IMPORTANCE: Amyotrophic lateral sclerosis (ALS) is a progressive, fatal disease with no known cause. Case studies primarily of athletes and several case-control studies have suggested that high levels of strenuous physical activity (PA) may increase the risk for ALS. This relationship has yet to be evaluated among women in population-based cohort studies. OBJECTIVE: To evaluate the relationship between PA and risk for ALS mortality in a large cohort of postmenopausal women. DESIGN, SETTING, AND PARTICIPANTS: The Women's Health Initiative (WHI) enrolled 161 809 postmenopausal women, aged 50 to 79 years (mean [SD] age, 63.6 [7.24] years), between 1993 and 1998 into either a clinical trial or an observational study at 40 clinical research centers across the United States. We conducted a cohort study from November 2014 to September 2015 using baseline and mortality data during an average of 9.6 years of follow-up from the entire WHI cohort, through September 1, 2013 (with 1.1% lost to follow-up), to address whether there is a relationship between PA and ALS mortality. EXPOSURES: The WHI assessed frequency and duration of mild, moderate, and strenuous PA at baseline via self-administered questionnaire. MAIN OUTCOMES AND MEASURES: Underlying cause of death from ALS collected from death certificates. RESULTS: The WHI enrolled 161 809 women, of whom 165 died of ALS; women who died of ALS were older (median age, 66 years; interquartile range, 61-69 years) compared with the total WHI study population (median age, 63 years; interquartile range, 57-69 years). Age-adjusted ALS mortality rates varied from 7.4 (95% CI, 5.5-9.9)/100 000 person-years for no strenuous PA to 10.6 (95% CI, 5.6-20.0)/100 000 person-years for strenuous PA 3 or more days per week (P = .07). Adjusted for age and body mass index (calculated as weight in kilograms divided by height in meters squared), the odds ratio for death from ALS for participants with strenuous PA 3 or more days per week compared with no reported strenuous PA was 1.56 (95% CI, 1.02-2.37; P = .04). CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first cohort study to report an increased risk for ALS mortality associated with strenuous PA in postmenopausal women. The association between strenuous PA and ALS risk observed does not compromise the overall benefit of strenuous PA for total mortality, coronary heart disease, and breast cancer reported in other WHI investigations, but it may provide an important clue to the etiology of ALS, if replicated by other studies.
IMPORTANCE: Amyotrophic lateral sclerosis (ALS) is a progressive, fatal disease with no known cause. Case studies primarily of athletes and several case-control studies have suggested that high levels of strenuous physical activity (PA) may increase the risk for ALS. This relationship has yet to be evaluated among women in population-based cohort studies. OBJECTIVE: To evaluate the relationship between PA and risk for ALSmortality in a large cohort of postmenopausal women. DESIGN, SETTING, AND PARTICIPANTS: The Women's Health Initiative (WHI) enrolled 161 809 postmenopausal women, aged 50 to 79 years (mean [SD] age, 63.6 [7.24] years), between 1993 and 1998 into either a clinical trial or an observational study at 40 clinical research centers across the United States. We conducted a cohort study from November 2014 to September 2015 using baseline and mortality data during an average of 9.6 years of follow-up from the entire WHI cohort, through September 1, 2013 (with 1.1% lost to follow-up), to address whether there is a relationship between PA and ALSmortality. EXPOSURES: The WHI assessed frequency and duration of mild, moderate, and strenuous PA at baseline via self-administered questionnaire. MAIN OUTCOMES AND MEASURES: Underlying cause of death from ALS collected from death certificates. RESULTS: The WHI enrolled 161 809 women, of whom 165 died of ALS; women who died of ALS were older (median age, 66 years; interquartile range, 61-69 years) compared with the total WHI study population (median age, 63 years; interquartile range, 57-69 years). Age-adjusted ALSmortality rates varied from 7.4 (95% CI, 5.5-9.9)/100 000 person-years for no strenuous PA to 10.6 (95% CI, 5.6-20.0)/100 000 person-years for strenuous PA 3 or more days per week (P = .07). Adjusted for age and body mass index (calculated as weight in kilograms divided by height in meters squared), the odds ratio for death from ALS for participants with strenuous PA 3 or more days per week compared with no reported strenuous PA was 1.56 (95% CI, 1.02-2.37; P = .04). CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first cohort study to report an increased risk for ALSmortality associated with strenuous PA in postmenopausal women. The association between strenuous PA and ALS risk observed does not compromise the overall benefit of strenuous PA for total mortality, coronary heart disease, and breast cancer reported in other WHI investigations, but it may provide an important clue to the etiology of ALS, if replicated by other studies.
Authors: Hannah Arem; Steven C Moore; Alpa Patel; Patricia Hartge; Amy Berrington de Gonzalez; Kala Visvanathan; Peter T Campbell; Michal Freedman; Elisabete Weiderpass; Hans Olov Adami; Martha S Linet; I-Min Lee; Charles E Matthews Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: Marianthi-Anna Kioumourtzoglou; Ran S Rotem; Ryan M Seals; Ole Gredal; Johnni Hansen; Marc G Weisskopf Journal: JAMA Neurol Date: 2015-08 Impact factor: 18.302
Authors: Anne McTiernan; Charles Kooperberg; Emily White; Sara Wilcox; Ralph Coates; Lucile L Adams-Campbell; Nancy Woods; Judith Ockene Journal: JAMA Date: 2003-09-10 Impact factor: 56.272
Authors: Sonja W de Jong; Mark H B Huisman; Nadia A Sutedja; Anneke J van der Kooi; Marianne de Visser; Helenius J Schelhaas; Kathelijn Fischer; Jan H Veldink; Leonard H van den Berg Journal: Am J Epidemiol Date: 2012-07-11 Impact factor: 4.897
Authors: Angela M Malek; Aaron Barchowsky; Robert Bowser; Terry Heiman-Patterson; David Lacomis; Sandeep Rana; Ada Youk; David Stickler; Daniel T Lackland; Evelyn O Talbott Journal: Neurodegener Dis Date: 2013-11-12 Impact factor: 2.977
Authors: I-Min Lee; Eric J Shiroma; Felipe Lobelo; Pekka Puska; Steven N Blair; Peter T Katzmarzyk Journal: Lancet Date: 2012-07-21 Impact factor: 79.321
Authors: Jennifer W Bea; Cynthia A Thomson; Robert B Wallace; Chunyuan Wu; Rebecca A Seguin; Scott B Going; Andrea LaCroix; Charles Eaton; Judith K Ockene; Michael J LaMonte; Rebecca Jackson; W Jerry Mysiw; Jean Wactawski-Wende Journal: Prev Med Date: 2016-12-06 Impact factor: 4.018
Authors: Jennifer W Bea; Scott B Going; Betsy C Wertheim; Tamsen L Bassford; Andrea Z LaCroix; Nicole C Wright; Jennifer S Nicholas; Steven B Heymsfield; Zhao Chen Journal: Prev Med Rep Date: 2018-05-09
Authors: Grace Xia Chen; Jeroen Douwes; Leonard H van den Berg; Bill Glass; David McLean; Andrea Martine 't Mannetje Journal: Acta Neurol Scand Date: 2022-03-31 Impact factor: 3.915